Publicaciones (63) Publicaciones en las que ha participado algún/a investigador/a

2015

  1. 2-fluoro-RNA oligonucleotide CD40 targeted aptamers for the control of B lymphoma and bone-marrow aplasia

    Biomaterials, Vol. 67, pp. 274-285

  2. A prognostic score to identify low-risk outpatients with acute deep vein thrombosis in the lower limbs

    American Journal of Medicine, Vol. 128, Núm. 1, pp. 90.e9-90.e15

  3. A prognostic score to identify low-risk outpatients with acute deep vein thrombosis in the upper extremity

    Journal of Thrombosis and Haemostasis, Vol. 13, Núm. 7, pp. 1274-1278

  4. Assessing complement blockade in patients with paroxysmal nocturnal hemoglobinuria receiving eculizumab

    Blood, Vol. 125, Núm. 5, pp. 775-783

  5. Atypical bullous pemphigoid with extensive cutaneous and mucosal erosions associated with chronic lymphocytic leukemia

    Journal of Dermatology

  6. Bortezomib, thalidomide and dexamethasone, with or without cyclophosphamide, for patients with previously untreated multiple myeloma: 5-year follow-up

    British Journal of Haematology, Vol. 171, Núm. 3, pp. 344-354

  7. CIP2A high expression is a poor prognostic factor in normal karyotype acute myeloid leukemia

    Haematologica

  8. Case Fatality Rates of Recurrent Thromboembolism and Bleeding in Patients Receiving Direct Oral Anticoagulants for the Initial and Extended Treatment of Venous Thromboembolism

    Journal of Cardiovascular Pharmacology and Therapeutics, Vol. 20, Núm. 5, pp. 490-500

  9. Chronic exposure to IFNα drives medullar lymphopoiesis towards t-cell differentiation in mice

    Haematologica, Vol. 100, Núm. 8, pp. 1014-1022

  10. Correlation of myelodysplastic syndromes with i(17)(q10) and TP53 and SETBP1 mutations

    British Journal of Haematology

  11. Critical analysis of the stringent complete response in multiple myeloma: Contribution of sFLC and bone marrow clonality

    Blood, Vol. 126, Núm. 7, pp. 858-862

  12. Cryopreservation of microencapsulated murine mesenchymal stem cells genetically engineered to secrete erythropoietin

    International Journal of Pharmaceutics, Vol. 485, Núm. 1-2, pp. 15-24

  13. Defining and treating high-risk multiple myeloma

    Leukemia, Vol. 29, Núm. 11, pp. 2119-2125

  14. Design, synthesis, and biological evaluation of novel matrix metalloproteinase inhibitors as potent antihemorrhagic agents: From hit identification to an optimized lead

    Journal of Medicinal Chemistry, Vol. 58, Núm. 5, pp. 2465-2488

  15. Direct-acting oral anticoagulants: Pharmacology, indications, management, and future perspectives

    European Journal of Haematology, Vol. 95, Núm. 5, pp. 389-404

  16. Discovery and Safety Profiling of a Potent Preclinical Candidate, (4-[4-[[(3 R)-3-(Hydroxycarbamoyl)-8-azaspiro[4.5]decan-3-yl]sulfonyl]phenoxy]- N -methylbenzamide) (CM-352), for the Prevention and Treatment of Hemorrhage

    Journal of Medicinal Chemistry, Vol. 58, Núm. 7, pp. 2941-2957

  17. Documento multidisciplinar de consenso sobre el manejo de la hemorragia masiva (documento HEMOMAS)

    Medicina Intensiva, Vol. 39, Núm. 8, pp. 483-504

  18. Efficacy of autologous melanocyte transplantation on amniotic membrane in patientswith stable leukoderma: A randomized clinical trial

    JAMA Dermatology

  19. Engineering Anti-myeloma Responses Using Affinity-Enhanced TCR-Engineered T Cells

    Cancer Cell

  20. Evaluation of clinical and biological prognostic factors in relapsed or refractory diffuse large B-cell lymphoma patients after previous treatment with rituximab and chemotherapy: Results of the PRO-R-IPI study

    Clinical Lymphoma, Myeloma and Leukemia, Vol. 15, Núm. 7, pp. 398-403